Viatris is a global pharmaceutical company with over 250 medicines on the World Health Organization’s List of Essential Medicines, which treat a range of conditions including cardiovascular, immunological, cancer, infectious diseases, and diabetes. Viatris products include generics and branded drugs such as Xanax, Lyrica, and Viagra. Viatris supplies medicines to 1 billion people around the world each year. The company also has a number of partnerships, including with the European Innovation Partnership on Active and Healthy Ageing, to improve prevention and treatment of noncommunicable diseases. The company was born from the merger of Mylan and Upjohn in 2020.
Viatris
Viatris in Fortune Rankings
- Company Information
- Change The World
- World's Best Workplaces
- Key Financials (last Fiscal Year)
- Profit Ratios
- Earnings Per Share (last Fiscal Year)
- Total Return
- Best Companies To Work For Europe
- Updated:10/08/2026
- Country/Territory:U.S.
- Headquarters:U.S.
- Industry:Pharmaceuticals
- CEO:Scott A. Smith
- Website:https://www.viatris.com
- Ticker:VTRS
- Company type:Public
- Revenues ($M):$14,300
- Profits ($M):$-3,515
- Market value ($M):$19,664
- Number of employees:30,000
Market Value as of Sep. 24, 2026. Sources: Regulatory filings; S&P Global.
- Impact Segment:Public Health/Nutrition
- Sector:Health Care
- World's Best list history:New
- Countries where the company was recognized on a GPTW national list:Albania, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Costa Rica, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greater China, Greece, Hungary, India, Italy, Kuwait, Latvia, Lithuania, Malaysia, Mexico, Morocco, The Netherlands, New Zealand, Nigeria, Norway, Panama, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, United Kingdom, United States, Vietnam, Zambia
- $ millions% change
- Revenues ($M):$14,299.9-3%
- Profits ($M):$-3,514.9-
- Assets ($M):$37,193.1-
- Total Stockholder Equity ($M):$14,711.3-
- Profit as % of Revenues:-24.6%
- Profits as % of Assets:-9.5%
- Profits as % of Stockholder Equity:-23.9%
- Earnings Per Share ($):-3.00
- EPS % Change (from prior fiscal year):-
- EPS % Change (5 year annual rate):-
- EPS % Change (10 year annual rate):-
- Total Return to Investors (last year):5%
- Total Return to Investors (5 year, annualized):-3.9%
- Total Return to Investors (10 year, annualized):-
- Sector:Health Care
- CEO/Top executive:Scott A. Smith
- Group headquarters:U.S.
- HQ location:U.S.
- GPTW national list:Albania, Bosnia and Herzegovina, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
- Woman CEO:no
- Number of Years on List:2
Viatris stock chart
Viatris in Fortune Rankings
- Fortune 500
- Fortune 100 Best Companies To Work For – Europe
- World’s 25 Best Workplaces
- Fortune Sector Leaders: Health Care
- Change the World